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Abstract From the time that it was granted US Food and
Drug Administration approval, neuromodulation has
secured a firm position in the treatment algorithm for
overactive bladder. With neuromodulation, physicians
were able to bridge the gap between the two ends of
the treatment spectrum (medical therapy and open
surgery). Sacral nerve stimulation has been the most
widely used form of neuromodulation. Recent modifica-
tions to its design, namely the development of the tined
lead and the launching of the refined InterStim II
(Medtronic, Minneapolis, MN), have made sacral nerve
simulation even less invasive and more effective. While
InterStim is maintaining a level of success with these
advancements, peripheral means of neuromodulation are
being explored. The current literature takes a closer look
at posterior tibial and pudendal nerve stimulation as
alternatives to sacral nerve stimulation. The field of
neuromodulation is also expanding in terms of the target
patient population, as it is being used to treat children,
patients with neurological disease, and others. As the
role of neuromodulation increases, we must continue to
assess its efficacy, safety, and cost-effectiveness in
comparison to other therapeutic options.
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Introduction
Overactive bladder (OAB) is defined as urgency with or
without urgency incontinence, usually with frequency
(>8 micturitions/24 h) and nocturia [1]. Conservative
management of OAB usually includes pelvic floor
physical therapy and/or use of pharmacotherapy such as
antimuscarinic medications. However, a significant num-
ber of patients are refractory to pharmacotherapy, and
long-term compliance is poor, so much so that only 30%
of individuals with OAB syndrome still take their
medication 1 year after initiation [2]. Traditionally,
patients who failed conservative measures were left with
highly invasive treatment options, such as myomectomy,
augmentation cystoplasty, and various urinary diversions
[3]. In 1997, the US Food and Drug Administration
approved neuromodulation for urgency incontinence, and
subsequently for urgency-frequency syndrome and non-
obstructive chronic urinary retention. Although its mode
of action is still not completely understood, recent
research indicates that this therapy involves not just
electrostimulation of sacral nerves but also neuromodula-
tion due to somatosensory bladder afferents projecting into
the pontine micturition center in the brainstem [4]. The
objective of this article is to review the current literature
and discuss the latest advances, significant trends, and
current debates in the treatment of OAB with neuro-
modulation. Of particular interest are the articles focusing
on peripheral nerve stimulation (PNS), cost-effectiveness,
and nontraditional patient populations.
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During the past year, several articles examined the
efficacy and cost-effectiveness of neuromodulation, as
well as the adverse effects and safety profile of this
procedure. In one such article, Siddiqui et al. [5￿]
systematically reviewed the literature regarding the effi-
cacy of sacral nerve stimulation (SNS) using the InterStim
(Medtronic, Minneapolis, MN) for women with refractory
OAB. The highest-quality data were found in three
independent studies of efficacy. In these studies, inconti-
nent episodes per day and pad usage significantly
decreased after SNS therapy. After SNS, there was a
significant decrease in mean incontinent episodes per day
(2–3 )a n dm e a nd a i l yp a du s e( 1 –3). About 45% of
patients reported “cure,” or lack of daily incontinence
episodes, up to 3 years after implant. Moreover, 54% of
patients maintained improvements in daily incontinence
episodes after implant. Subjective outcomes were also
assessed and shown to be beneficial. Amundsen et al. [6]
reported a 65- to 67-point decrease in Incontinence Impact
Questionnaire (IIQ) scores 2 years after SNS implant.
Inasepa ratearticle,Sidd iquietal.[7￿￿] compared the cost-
effectiveness of SNS versus that of intravesical botulinum A
toxin (BoNT-A) for treatment of refractory urge inconti-
nence. Using the Markov decision model to compare cost
(2008 US dollars) and effectiveness (quality-adjusted life-
years [QALYs]), they calculated the incremental cost-
effectiveness ratio (ICER), which compares the difference
in cost with the difference in effectiveness (ie, QALYs). In
the best-case scenario, SNS was more expensive ($15,743 vs
$4,392) and more effective (1.73 vs 1.63 QALYs) than
BoNT-A during a 2-year period. During a 2-year period, the
ICER was $116,427 per QALY, indicating that although SNS
was more effective, BoNT-A was the more cost-effective
option. One could argue that the cost-effectiveness compar-
ison could change dramatically if it were recalculated beyond
the 2-year period. However, the authors were limited to a 2-
year period because long-term data regarding BoNT-A
injections are limited.
In addition to demonstrating that this procedure is
effective, the literature also suggests that neuromodulation
is relatively safe. Six good studies were available regarding
adverse events associated with SNS [5￿]. Adverse events
mainly encompassed pain, infection, and change in clinical
effect, often due to lead migration. The surgical revision
rates when using tined leads ranged from 3% to 16%, as
most complications were managed conservatively. Six
percent of patients were explanted due to lack of efficacy,
and 5% to 11% were explanted due to infection.
Another safety issue regarding sacral neuromodulation
is the potential for cross-talk between the InterStim
device and cardiac pacemakers. Roth [8] recently pre-
sented a series of three patients with cardiac pacemakers
who subsequently underwent staged SNS implantation,
and two patients who had successful internal pulse
generator (IPG) implantation who later required cardiac
pacemaker implantation. Patients had continuous cardiac
monitoring by anesthesia, and there were no observed
changes in rhythm perioperatively. This case series
includes the two patients who did not have their IPGs
turned off at the time of cardiac pacemaker implantation.
At the time of 2-week follow-up, interrogation of the IPGs
revealed that the settings had remained the same on both
devices. The IPGs were all programmed for continuous
bipolar stimulation. They were implanted on the contra-
lateral side of the cardiac pacemakers in the three patients
who had previously undergone cardiac pacemaker place-
ment. Of note, none of the pacemakers had cardioversion
or defibrillator capabilities. Based on this study, SNS can
be safely used in patients with cardiac pacemakers.
Alternatives to Sacral Nerve Stimulation
Posterior Tibial Nerve Stimulation
During the past year, the bulk of the literature regarding
advancements in neuromodulation for OAB has focused on
alternatives to SNS. The literature suggests that PNS via the
posterior tibial nerve or the pudendal nerve may be viable
options. Posterior tibial nerve stimulation (PTNS) was first
introduced by McGuire and colleagues in 1983, and more
recent studies have confirmed a 60% to 80% positive
response rate after 10 to 12 weekly treatments [9]. PTNS is
performed by inserting a 34-gauge needle about 3 to 4 cm
cephalad to the medial malleous, between the posterior
margin of the tibia and soleus muscle. Once connected, an
adjustable voltage pulse intensity of 0 to 10 mA, a fixed
pulse width of 200, and a frequency of 20 Hz were
delivered during weekly 30-min sessions. Correct position
is confirmed by flexion of the great toe or fanning of the
toes and a tingling sensation. Adverse events associated
with PTNS are minimal, mostly minor hematomas at the
site of needle insertion.
Peters et al. [10￿] published a randomized, multicenter
study that compared the efficacy of PTNS with that of
extended-release tolterodine, also known as the OrBIT
(Overactive Bladder Innovative Therapy) trial. A total of
100 adults with urinary frequency were randomly assigned
to 12 weeks of treatment with PTNS or 4 mg/d of extended-
release tolterodine. After 12 weeks of therapy, the PTNS
arm reported a 79.5% cure or improvement rate, compared
with 54.8% of those on tolterodine (P=0.01) on the global
response assessments. The two groups had similar improve-
ments on objective measures, including reductions in
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severity, and nighttime voids, and increased voided volume.
The authors concluded that PTNS was safe and efficacious,
with statistically significant subjective and objective
improvements comparable to that of pharmacotherapy.
Peters et al. [11￿] also compared the efficacy of PTNS to
that of sham in a multicenter, double-blind, randomized
trial known as SUmiT (Study of Urgent PC Versus Sham
Effectiveness in Treatment of Overactive Bladder Symp-
toms). After 12 weeks, 54.5% of the PTNS patients
reported moderate or markedly improved response from
baseline, compared with 20.9% of sham patients (P<
0.001). PTNS also increased voided volume when com-
pared with baseline from 83 to 169.5 mL (P=0.01). Patients
were not able to correctly identify if they were part of the
sham or PTNS group, as both groups had leads placed. The
results from this study suggest that the therapeutic effect of
PTNS is a result of stimulation of the posterior tibial nerve
and not a placebo effect.
Following the encouraging results from the SUmiT and
OrBIT studies demonstrating true therapeutic effects com-
parable to those of tolterodine, other authors focused on
various treatment courses and durability. The traditional
PTNS treatment course runs for 12 weeks, with weekly 30-
min sessions. Yoong et al. [12] reported initial outcome
data following a shortened 6-week treatment protocol with
PTNS. Forty-three women underwent this shortened treat-
ment course and were evaluated with bladder symptom
diaries and the Incontinence Impact Questionnaire (IIQ-7),
which is a health-related quality-of-life questionnaire. A
positive response to therapy was defined as 1) OAB
symptoms no longer being bothersome, 2) reduction by
half in frequency episodes, and 3) reduction by 25% in IIQ-
7 outcomes. The positive response rate was 69.7%, with an
almost 50% decrease in the median daytime and nocturnal
frequency (11.8 vs 6.9 and 3.5 vs 1.8; P<0.05). Patients
reported fewer urge incontinence episodes per 24 h, from a
median of 3.5 to 2.4 (P<0.05). The median IIQ-7 scores
decreased by 25% (30.4 vs 24.3; P<0.05), and the median
number of pads used in 24 hours decreased by 34% (3.8 vs
2.5; P<0.05). However, the participants reported return of
symptoms 3 weeks after the treatment, and no predictors of
duration of symptomatic relief could be identified. These
early data suggest that the PTNS treatment course can be
halved, but more conclusive studies are needed to deter-
mine the optimal duration of initial treatment and mainte-
nance program.
The question of durability of PTNS treatment was addressed
by MacDiarmid et al. [13￿] in the second phase of the OrBIT
study. Thirty-three of the 35 responders from the initial
12-week treatment course elected for maintenance ther-
apy. Participants selected treatment intervals allowing
them to control OAB symptoms at an acceptable level. A
total of 32 completed 6 months of maintenance, and 25
completed 12 months. The participants received a mean
of 12.1±4.9 treatments over an average of 263 days,
with a mean of 21 days (median, 17) between treatments.
However, the participants had longer time intervals
during the second 6 months than during the first 6 months
of the evaluation (14 vs 24 days). Subjective global
assessments showed a sustained improvement of symp-
toms from 12 weeks at the 6-month and 12-month
evaluations (94% and 96%, respectively). There were
also objective improvementsfrombaseline,withdecreases of
2.8 voids per day (P<0.001), 1.6 urge incontinence episodes
per day (P<0.001), 0.8 nocturnal voids (P<0.05), and an
increase of 39 mL in voided volume (P<0.01). The authors
concluded that PTNS can be a viable long-term therapeutic
option for OAB patients.
A global evaluation of PTNS as a treatment option for
OAB was performed by Ridout and Yoong [9] with a
review of the published literature. Six articles were
identified that assessed the efficacy of PTNS as therapy
for OAB. These studies used various criteria for “positive
response,” such as objective reduction in symptoms and the
request for maintenance therapy following completion of
the 12-week course. Using these varying definitions of
success, PTNS has been reported to have a 60% to 81%
response rate. Most authors agree that PTNS requires
indefinite maintenance therapy, but the specifics of the
maintenance program have not yet been defined. Van der
Pal et al. [14] showed that 64% of patients reported greater
than 50% worsening in frequency and incontinence
episodes after a 6-week pause in treatment. Overall, PTNS
seems to offer symptomatic relief for OAB patients who are
refractory to conservative therapy, but standard guidelines
for initial therapy and maintenance regimens are lacking.
Pudendal Neuromodulation
In addition to the sacral and the posterior tibial nerves,
physicians can target the pudendal nerves for neuromodu-
lation. The sacral nerve sensory afferent fibers originate in
the pudendal nerve, which innervates the pelvic floor
muscles, external urethral and anal sphincters, and pelvic
organs. Peters et al. [15] performed a retrospective review
of patients undergoing tined lead placement at the pudendal
nerve via the ischial-rectal approach for chronic pudendal
neuromodulation. There were 84 patients with various
primary urologic diagnoses, including interstitial cystitis/
painful bladder syndrome, urgency/frequency or urge
incontinence, nonobstructive urinary retention, and pelvic/
bladderpainwithoutinterstitialcystitis.Almostallindividuals
with a history of failed sacral neuromodulation responded to
the pudendal lead stimulation (93.2% [41 of 44]). Overall,
positive pudendal response (≥50% improvement on the
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These are encouraging results that warrant further investiga-
tion and suggest that pudendal nerve–targeted neuromodula-
tion may be a viable alternative to SNS.
Technological Development
Since its introduction, Medtronic has made some advance-
ment in the design of the SNS device. The introduction of
the tined lead 5 years ago changed sacral neuromodulation
from a single-stage open surgery requiring general anes-
thesia to a two-stage, minimally invasive, percutaneous
procedure with local anesthesia. Because there is less lead
migration, the permanent tined lead allows for a longer trial
period, during which the physician and patient can
reprogram the device until they achieve optimal settings.
As a result of this extended test period, the technical failure
rate has decreased, and the response rate has almost
doubled to approximately 80% [3].
The most recent technological development in the Inter-
StimapparatushasbeentheInterStimIIdevice.TheInterStim
II received its regulatory approval in 2006. Like its prototype,
the InterStim II is an implantable neurostimulator but is 50%
lighter and smaller. This change purportedly increases patient
comfort and makes the implant procedure easier and quicker
for the surgeon [3]. A postmarket, Web-based survey among
11 European experts in urology, gynecology, and gastroen-
terology evaluated their initial experience with the new
InterStim II therapy in 55 patients [16]. The less bulky
InterStim II implantable neurostimulator allowed for a tinier
incision and shallower pocket (3.5 cm less), which made
implantation more tolerable, especially for thinner patients.
Moreover, the new device does not require an extension
cable, which reduced operative time. The new small iCon
patient programmer also offers the patient more flexibility,
with four preset programs to optimize the response rate.
Novel Applications
During the past year, several authors reported their experience
with sacral neuromodulation in nontraditional patient popula-
tions, including patients with neurogenic detrusor overactivity,
failed augmentation cystoplasty, and children. A recent article
from Italy looked at PTNS as a treatment option for children
with lower urinary tract dysfunction [17]. Forty-four children
with a variety of urologic diagnoses (including idiopathic
OAB, dysfunctional voiding, underactive bladder, underactive
valve bladder, and neurogenic bladder) were enrolled in a
prospective clinical trial of PTNS efficacy. A total of 25 were
female and 18 were male (average age, 10.7±4.8 years). They
underwent the conventional 12-week course of PTNS with
weekly 30-min sessions. Follow-up assessment was per-
formed every 6 months for 2 years after treatment. Symp-
tomatic improvement was greater in non-neurogenic than in
neurogenic cases (78% vs 14%; P<0.002). At 1-year follow-
up, the cure rate was greater in dysfunctional voiding than in
OAB cases (71% vs 41%), and it remained the same at
2 years. Chronic neuromodulation was required to maintain
results in 29% of patients with dysfunctional voiding and 50%
of patients with OAB. Thus, PTNS appears to be a viable
option for treating pediatric lower urinary tract dysfunction,
especially in non-neurogenic cases.
As in the pediatric population, lower urinary tract
dysfunction is also common in adults with neurological
disease. However, apart from spinal cord injury patients,
neuromodulation is not commonly offered to this group of
patients.VanReyandHeesakkers[18￿] wrote a review article
on the applications of neurostimulation for urinary storage
and voiding dysfunction in neurological patients. This article
reviewed the use and results of pudendal nerve stimulation,
SNS, and lower limb stimulation in patients with neurogenic
detrusor overactivity. Some evidence has demonstrated SNS
efficacy in treating neurogenic bladder disorders in multiple
sclerosis patients, but this population has a chance of
negative test stimulation that is four times higher [18￿].
Pudendal nerve stimulation via dorsal penile/clitoral nerve
stimulation has been shown to benefit spinal cord injury
patients by increasing cystometric capacity and inhibiting
neurogenic bladder overactivity [19]. The current use of
pudendal nerve stimulation is limited by a lack of reliable
stimulation technique, as pudendal nerve stimulation via
tined leads and surface electrodes is still in the preliminary
stages. As a third alternative to sacral and pudendal nerve
stimulation, PTNS also has been reported to be effective for
a patient population of individuals with multiple sclerosis,
myelitis, incomplete spinal cord injury, stroke, and
Parkinson’sd i s e a s e[ 20, 21]. These studies suggest there
is significant benefit to neuromodulation among this
special patient population that warrants further study.
Part of the advantage of SNS is that it provides treatment
for refractory OAB patients without requiring extensive
surgery (eg, augmentation cystoplasty). However, some
patients have already undergone augmentation cystoplasty
and continue to suffer with OAB symptoms. Rasmussen et
al. [21] reported on their case series of two such patients
who were treated with sacral neuromodulation. One patient
continued to void every 30 to 60 min despite medical
therapy, intravesical treatment with BoNT-A, and augmen-
tation cystoplasty. This patient ultimately underwent staged
sacral approach implantation and was able to wait 3 h
between voids during the trial period. She had durable
improvement at 14 months of follow-up after the second-
stage implantation. The second patient had undergone a
supratrigonal ileocystoplasty but still voided every 1.5 h
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sacral neuromodulator implantation, she was able to wait 3
to 4 h, and her voided volume ranged from 300 to 500 mL.
Her improvements have persisted with a follow-up of
17 months. Both patients had videourodynamics as part of
their preoperative assessment, which demonstrated good
compliance and capacity. This case series indicates that
SNS may be an important adjunctive therapy for patients
with truly refractory OAB despite bladder augmentation.
Conclusions
During the past year, the literature regarding neuromodulation
for treating OAB has focused heavily on validating PTNS and
pudendal nerve stimulation as reasonable alternatives to SNS.
Other significant articles re-examined SNS in terms of safety,
efficacy, and cost-effectiveness. The general conclusion is that
neuromodulation is an efficacious and safe treatment option for
patients with medically refractory OAB. The inclusion criteria
for SNS treatment have expanded to embrace the neurogenic
andpediatricpopulations,aswellasthosewhohaveundergone
augmentation cystoplasty. Future efforts should focus on
defining optimal treatment and maintenance schedules for less
invasive PTNS and reporting the preliminary experience with
the new InterStim II device. The current developments in
technology and clinical applicability will continue to broaden
the field of neuromodulation for urologic patients.
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